



Supplemental Fig 1. Distribution of time to treatment by stage.

Supplemental Table I. Demographic characteristics

Characteristic	<30 d (n = 81,268)	30-59 d (n = 56,246)	60-89 d (n = 10,967)	90-119 d (n = 2779)	>119 d (n = 1958)	P value
Age at diagnosis, y						<.001
<30	4529 (5.6)	2754 (4.9)	530 (4.8)	109 (3.9)	105 (5.4)	
30-39	7455 (9.2)	4544 (8.1)	813 (7.4)	198 (7.1)	154 (7.9)	
40-49	13,379 (16.5)	8679 (15.4)	1468 (13.4)	350 (12.6)	231 (11.8)	
50-59	17,792 (21.9)	11,795 (21.0)	2294 (20.9)	549 (19.8)	394 (20.1)	
60-69	17,282 (21.3)	12,200 (21.7)	2373 (21.6)	612 (22.0)	398 (20.3)	
70-79	13,750 (16.9)	10,423 (18.5)	2126 (19.4)	565 (20.3)	387 (19.8)	
≥80	7081 (8.7)	5851 (10.4)	1363 (12.4)	396 (14.2)	289 (14.8)	
Sex						<.001
Female	35,607 (43.8)	23,879 (42.5)	4500 (41.0)	1124 (40.4)	826 (42.2)	
Male	45,661 (56.2)	32,367 (57.5)	6467 (59.0)	1655 (59.6)	1132 (57.8)	
Race						<.001
White	79,335 (97.6)	54,845 (97.5)	10,676 (97.3)	2676 (96.3)	1883 (96.2)	
Black	318 (0.4)	312 (0.6)	90 (0.8)	39 (1.4)	32 (1.6)	
Asian	113 (0.1)	92 (0.2)	28 (0.3)	10 (0.4)	10 (0.5)	
Pacific Islander	25 (0.0)	9 (0.0)	1 (0.0)	1 (0.0)	1 (0.1)	
American Indian, Aleutian, Eskimo	68 (0.1)	57 (0.1)	10 (0.1)	4 (0.1)	3 (0.2)	
Other	297 (0.4)	190 (0.3)	41 (0.4)	8 (0.3)	10 (0.5)	
Unknown	1112 (1.4)	741 (1.3)	121 (1.1)	41 (1.5)	19 (1.0)	
Charlson-Deyo comorbidity score						<.001
0	72,267 (88.9)	49,286 (87.6)	9523 (86.8)	2345 (84.4)	1677 (85.6)	
1	7717 (9.5)	5822 (10.4)	1202 (11.0)	357 (12.8)	229 (11.7)	
≥2	1284 (1.6)	1138 (2.0)	242 (2.2)	77 (2.8)	52 (2.7)	
Insurance type/status						<.001
Medicare	27,466 (33.8)	20,811 (37.0)	4359 (39.7)	1183 (42.6)	820 (41.9)	
Medicaid	1323 (1.6)	1174 (2.1)	361 (3.3)	124 (4.5)	98 (5.0)	
Private insurance/managed care	48,124 (59.2)	31,103 (55.3)	5463 (49.8)	1270 (45.7)	866 (44.2)	
Other government	653 (0.8)	559 (1.0)	125 (1.1)	36 (1.3)	34 (1.7)	
Not insured	1870 (2.3)	1462 (2.6)	377 (3.4)	109 (3.9)	77 (3.9)	
Insurance status unknown	1832 (2.3)	1137 (2.0)	282 (2.6)	57 (2.1)	63 (3.2)	
Distance from hospital	32.28 (112.93)	34.98 (99.96)	39.48 (107.76)	38.21 (91.61)	41.73 (109.60)	<.001
Facility type						<.001
Academic/research program	29,153 (35.9)	26,784 (47.6)	6001 (54.7)	1498 (53.9)	998 (51.0)	
Community cancer program	5329 (6.6)	2831 (5.0)	455 (4.1)	130 (4.7)	94 (4.8)	
Comprehensive community cancer program	30,504 (37.5)	16,713 (29.7)	2682 (24.5)	715 (25.7)	532 (27.2)	
Integrated network cancer program	5217 (6.4)	3219 (5.7)	590 (5.4)	159 (5.7)	96 (4.9)	
Other	52 (0.1)	24 (0.0)	6 (0.1)	1 (0.0)	1 (0.1)	
Unknown	11,013 (13.6)	6675 (11.9)	1233 (11.2)	276 (9.9)	237 (12.1)	
Facility location						<.001
East north central	11,169 (13.7)	8442 (15.0)	1847 (16.8)	428 (15.4)	291 (14.9)	
East south central	6190 (7.6)	3027 (5.4)	428 (3.9)	121 (4.4)	79 (4.0)	
Middle Atlantic	7978 (9.8)	9330 (16.6)	2052 (18.7)	513 (18.5)	337 (17.2)	
Mountain	3744 (4.6)	2258 (4.0)	398 (3.6)	112 (4.0)	72 (3.7)	
New England	4117 (5.1)	3502 (6.2)	591 (5.4)	170 (6.1)	110 (5.6)	
Pacific	8130 (10.0)	6326 (11.2)	1497 (13.7)	455 (16.4)	331 (16.9)	
South Atlantic	16,808 (20.7)	11,692 (20.8)	2147 (19.6)	497 (17.9)	340 (17.4)	
West North Central	7821 (9.6)	3085 (5.5)	428 (3.9)	99 (3.6)	83 (4.2)	
West South Central	4298 (5.3)	1909 (3.4)	346 (3.2)	108 (3.9)	78 (4.0)	
Unknown	11,013 (13.6)	6675 (11.9)	1233 (11.2)	276 (9.9)	237 (12.1)	
Primary site						<.001
Head and neck	14,776 (18.2)	12,645 (22.5)	3134 (28.6)	878 (31.6)	645 (32.9)	
Upper extremities	21,891 (26.9)	14,270 (25.4)	2508 (22.9)	612 (22.0)	439 (22.4)	
Trunk	27,507 (33.8)	17,864 (31.8)	3186 (29.1)	744 (26.8)	483 (24.7)	

Continued

Supplemental Table I. Cont'd

Characteristic	<30 d (n = 81,268)	30-59 d (n = 56,246)	60-89 d (n = 10,967)	90-119 d (n = 2779)	>119 d (n = 1958)	P value
Lower extremities	16,620 (20.5)	11,146 (19.8)	2054 (18.7)	524 (18.9)	369 (18.8)	
Not specified	474 (0.6)	321 (0.6)	85 (0.8)	21 (0.8)	22 (1.1)	
Laterality						<.001
Left	35,123 (43.2)	24,023 (42.7)	4600 (41.9)	1124 (40.4)	779 (39.8)	
Midline	8486 (10.4)	6525 (11.6)	1426 (13.0)	390 (14.0)	291 (14.9)	
Right	32,326 (39.8)	22,377 (39.8)	4309 (39.3)	1128 (40.6)	790 (40.3)	
Unknown	5333 (6.6)	3321 (5.9)	632 (5.8)	137 (4.9)	98 (5.0)	
Histologic type						<.001
Superficial spreading	26,264 (32.3)	18,058 (32.1)	3125 (28.5)	736 (26.5)	498 (25.4)	
Nodular	8140 (10.0)	6350 (11.3)	1341 (12.2)	331 (11.9)	239 (12.2)	
Lentigo maligna	3487 (4.3)	2635 (4.7)	622 (5.7)	174 (6.3)	132 (6.7)	
Acral lentiginous	1023 (1.3)	1004 (1.8)	250 (2.3)	72 (2.6)	55 (2.8)	
Desmoplastic	980 (1.2)	1068 (1.9)	297 (2.7)	78 (2.8)	64 (3.3)	
Spindle	919 (1.1)	958 (1.7)	219 (2.0)	65 (2.3)	51 (2.6)	
Amelanotic	102 (0.1)	74 (0.1)	15 (0.1)	3 (0.1)	2 (0.1)	
Other	630 (0.8)	501 (0.9)	110 (1.0)	22 (0.8)	17 (0.9)	
Unspecified	39,723 (48.9)	25,598 (45.5)	4988 (45.5)	1298 (46.7)	900 (46.0)	
Breslow depth						<.001
<1 mm	45,525 (56.0)	29,018 (51.6)	5183 (47.3)	1259 (45.3)	925 (47.2)	
1.01-2.00 mm	1,7350 (21.3)	12,548 (22.3)	2395 (21.8)	603 (21.7)	373 (19.1)	
2.01-4 mm	10,289 (12.7)	7893 (14.0)	1651 (15.1)	402 (14.5)	274 (14.0)	
>4 mm	5969 (7.3)	5410 (9.6)	1429 (13.0)	415 (14.9)	301 (15.4)	
Not specified	2135 (2.6)	1377 (2.4)	309 (2.8)	100 (3.6)	85 (4.3)	
Ulceration						<.001
Not present	63,033 (77.6)	43,423 (77.2)	8243 (75.2)	2014 (72.5)	1404 (71.7)	
Present	1319 (1.6)	1005 (1.8)	256 (2.3)	64 (2.3)	44 (2.2)	
Unknown	16,916 (20.8)	11,818 (21.0)	2468 (22.5)	701 (25.2)	510 (26.0)	
Lymphovascular invasion						<.001
Not present	22,525 (27.7)	16,374 (29.1)	3088 (28.2)	777 (28.0)	521 (26.6)	
Present	1212 (1.5)	968 (1.7)	236 (2.2)	62 (2.2)	46 (2.3)	
Unknown	57,531 (70.8)	38,904 (69.2)	7643 (69.7)	1940 (69.8)	1391 (71.0)	
TNM pathologic stage						<.001
Stage I	55,309 (68.1)	36,167 (64.3)	6478 (59.1)	1518 (54.6)	1082 (55.3)	
Stage II	15,725 (19.3)	12,194 (21.7)	2600 (23.7)	685 (24.6)	464 (23.7)	
Stage III	10,234 (12.6)	7885 (14.0)	1889 (17.2)	576 (20.7)	412 (21.0)	
Living status						<.001
Alive	67,635 (83.2)	45,913 (81.6)	8591 (78.3)	2103 (75.7)	1453 (74.2)	
Dead	1,3633(16.8)	10,333(18.4)	2376 (21.7)	676 (24.3)	505 (25.8)	
Year of diagnosis						<.001
2004	7732 (9.5)	4653 (8.3)	875 (8.0)	219 (7.9)	168 (8.6)	
2005	8344 (10.3)	5488 (9.8)	1047 (9.5)	254 (9.1)	186 (9.5)	
2006	8864 (10.9)	5757 (10.2)	1127 (10.3)	313 (11.3)	213 (10.9)	
2007	8629 (10.6)	6027 (10.7)	1204 (11.0)	288 (10.4)	216 (11.0)	
2008	8441 (10.4)	6229 (11.1)	1204 (11.0)	305 (11.0)	208 (10.6)	
2009	8777 (10.8)	6261 (11.1)	1311 (12.0)	318 (11.4)	220 (11.2)	
2010	9560 (11.8)	6534 (11.6)	1249 (11.4)	302 (10.9)	218 (11.1)	
2011	10,286 (12.7)	7219 (12.8)	1346 (12.3)	377 (13.6)	266 (13.6)	
2012	10,635 (13.1)	8078 (14.4)	1604 (14.6)	403 (14.5)	263 (13.4)	

Supplemental Table II. Multivariate analysis of overall survival across all stages

Characteristic	Hazard Ratio	95% CI	P value
Age at diagnosis			
<30	Reference		
30-39	1.22	1.08-1.38	.001
40-49	1.34	1.08-1.65	.007
50-59	1.61	1.31-1.98	<.001
60-69	2.03	1.64-2.49	<.001
70-79	3.24	2.63-4.00	<.001
≥80	6.31	5.11-7.78	<.001
Sex			
Female	Reference		
Male	1.37	1.33-1.41	<.001
Charlson-Deyo comorbidity score			
0	Reference		
1	1.29	1.24-1.33	<.001
≥2	2.08	1.96-2.20	<.001
Insurance type/status			
Unknown	Reference		
Medicaid	1.64	1.46-1.83	<.001
Medicare	1.13	1.04-1.24	.03
Not insured	1.35	1.21-1.51	<.001
Other government	1.18	1.01-1.38	.14
Private insurance/managed care	0.83	0.76-0.90	<.001
Facility type (%)			
Academic/research program	Reference		
Community cancer program	1.18	1.13-1.24	<.001
Comprehensive community cancer program	1.06	1.03-1.09	<.001
Integrated network cancer program	1.11	1.05-1.16	<.001
Other	0.88	0.47-1.63	.62
Facility location (%)			
East north central	Reference		
East south central	1.18	1.12-1.24	<.001
Middle Atlantic	0.94	0.90-0.99	.02
Mountain	1.00	0.94-1.06	.97
New England	0.92	0.87-0.97	.007
Pacific	0.92	0.88-0.97	<.001
South Atlantic	1.01	0.97-1.05	.77
West north central	0.99	0.94-1.04	.47
West south central	1.10	1.04-1.17	<.001
Unknown	0.81	0.67-0.98	.03
Primary site			
Head and neck	Reference		
Lower extremities	0.71	0.68-0.74	<.001
Overlapping	0.71	0.56-1.11	<.001
Trunk	0.85	0.82-0.89	<.001
Upper extremities	0.77	0.74-0.80	<.001
Not specified	0.88	0.77-1.02	.03

Continued

Supplemental Table II. Cont'd

Characteristic	Hazard Ratio	95% CI	P value
Laterality			
Left	Reference		
Midline	1.12	1.07-1.17	<.001
Right	1.00	0.97-1.03	.9
Unknown	1.1	1.05-1.16	<.001
Histologic type			
Superficial spreading	Reference		
Lentigo maligna	1.07	1.01-1.14	.04
Acral lentiginous	1.30	1.20-1.42	<.001
Amelanotic	0.82	0.56-1.19	.3
Nodular	1.13	1.09-1.18	<.001
Desmoplastic	0.79	0.72-0.86	<.001
Spindle	0.91	0.83-0.99	.01
Other	1.03	0.90-1.18	.69
Unspecified	1.06	1.03-1.09	<.001
Breslow depth			
<1 mm	Reference		
1.01-2.00 mm	1.12	1.08-1.16	<.001
2.01-4.00 mm	1.25	1.19-1.30	<.001
>4 mm	1.80	1.72-1.88	<.001
Unknown	1.24	1.16-1.33	<.001
Ulceration			
Not present	Reference		
Present	5.69	5.40-5.99	<.001
Unknown	1.28	1.24-1.31	<.001
Lymphovascular invasion			
Not present	Reference		
Present	1.74	1.60-1.88	<.001
Unknown	1.11	1.11-1.16	<.001
TNM pathologic stage			
Stage I	Reference		
Stage II	1.57	1.51-1.64	<.001
Stage III	3.28	3.15-3.41	<.001
Time to surgery			
1-29 d	Reference		
30-59 d	1.02	0.99-1.04	.12
60-89 d	1.03	0.99-1.08	.09
90-119 d	1.09	1.01-1.18	.03
≥120 d	1.12	1.02-1.22	.02

CI, Confidence interval.

Supplemental Table III. Multivariate analysis of melanoma for TNM stage I

Characteristic	Hazard ratio	95% CI	P value
Age at diagnosis			
<30	Reference		
30-39	1.52	1.13-2.04	.005
40-49	2.23	1.7-2.93	<.001
50-59	3.35	2.57-4.36	<.001
60-69	4.75	3.65-6.18	<.001
70-79	8.68	6.66-11.32	<.001
≥80	21.66	16.6-28.26	<.001
Sex			
Female	Reference		
Male	1.48	1.41-1.55	<.001
Charlson-Deyo comorbidity score			
0	Reference		
1	1.45	1.37-1.54	<.001
≥2	2.51	2.27-2.77	<.001
Insurance type/status			
Medicare	Reference		
Medicaid	1.6	1.34-1.91	<.001
Private insurance/ managed care	0.65	0.61-0.69	<.001
Other government	0.94	0.74-1.21	.648
Not insured	1.11	0.93-1.33	.264
Insurance status unknown	0.74	0.63-0.87	<.001
Facility type			
Academic/research program	Reference		
Community cancer program	1.19	1.1-1.29	<.001
Comprehensive community cancer program	1.06	1.01-1.11	.017
Integrated network cancer program	1.13	1.04-1.23	.004
Other	0.78	0.25-2.43	.671
Facility location			
East north central	Reference		
East south central	1.16	1.06-1.26	.001
Middle Atlantic	0.92	0.86-1	.042
Mountain	1	0.9-1.12	.942
New England	0.92	0.84-1.01	.091
Pacific	0.87	0.81-0.95	.001
South Atlantic	0.96	0.9-1.03	.292
West north central	0.96	0.88-1.05	.42
West south central	1.08	0.97-1.2	.165
Primary site			
Head and neck	Reference		
Trunk	0.77	0.73-0.82	<.001
Upper extremities	0.76	0.71-0.8	<.001
Lower extremities	0.63	0.58-0.68	<.001
Not specified	1	0.77-1.3	.982

Continued

Supplemental Table III. Cont'd

Characteristic	Hazard ratio	95% CI	P value
Laterality			
Left	Reference		
Midline	1.11	1.03-1.19	.007
Right	0.99	0.95-1.04	.74
Unknown	1.15	1.06-1.24	.001
Histologic type			
Superficial spreading	Reference		
Acral lentiginous	1.25	1.03-1.51	.022
Amelanotic	1.26	0.57-2.82	.568
Desmoplastic	0.83	0.67-1.04	.104
Lentigo maligna	1	0.93-1.08	.931
Nodular	1.27	1.15-1.4	<.001
Spindle	1	0.82-1.21	.973
Other	0.65	0.47-0.88	.005
Unspecified	1.04	0.99-1.09	.107
Breslow depth			
<1 mm	Reference		
1.01-2.00 mm	1.35	1.29-1.41	<.001
Ulceration			
Not present	Reference		
Present	7.11	5.9-8.58	<.001
Unknown	1.22	1.14-1.31	<.001
Lymphovascular invasion			
Not present	Reference		
Present	1.41	0.94-2.09	.093
Unknown	1.02	0.94-1.11	.597
Time to treatment			
1-29 d	Reference		
30-59 d	1.05	1.01-1.1	.029
60-89 d	1.16	1.07-1.25	<.001
90-119 d	1.29	1.12-1.48	<.001
≥120 d	1.41	1.21-1.65	<.001

CI, Confidence interval.

Supplemental Table IV. Multivariate analysis of melanoma by TNM stage II

Characteristic	Hazard ratio	95% CI	P value
Age at diagnosis			
<30	Reference		
30-39	1.26	0.94-1.68	.115
40-49	1.39	1.07-1.82	.015
50-59	1.6	1.24-2.07	<.001
60-69	1.88	1.45-2.43	<.001
70-79	2.87	2.21-3.73	<.001
≥80	5.26	4.05-6.82	<.001
Sex			
Female	Reference		
Male	1.26	1.2-1.33	<.001
Charlson-Deyo comorbidity score			
0	Reference		
1	1.25	1.17-1.33	<.001
≥2	1.95	1.75-2.16	<.001
Insurance type/status			
Medicare	Reference		
Medicaid	1.24	1.04-1.48	.015
Private insurance/managed care	0.79	0.73-0.84	<.001
Other government	1.05	0.81-1.36	.726
Not insured	1.13	0.96-1.34	.136
Insurance status unknown	0.93	0.76-1.14	.488
Facility type			
Academic/research program	Reference		
Community cancer program	1.23	1.12-1.34	<.001
Comprehensive community cancer program	1.06	1.01-1.11	.028
Integrated network cancer program	1.17	1.07-1.28	.001
Other	1.41	0.53-3.76	.495
Facility location			
East north central	Reference		
East south central	1.13	1.02-1.24	.017
Middle Atlantic	0.96	0.88-1.04	.33
Mountain	1.01	0.9-1.13	.879
New England	0.92	0.82-1.02	.113
Pacific	0.95	0.87-1.04	.248
South Atlantic	1.03	0.96-1.11	.44
West north central	0.95	0.86-1.05	.328
West south central	1.18	1.04-1.32	.008
Primary site			
Head and neck	Reference		
Trunk	0.95	0.89-1.03	.203
Upper extremities	0.85	0.79-0.91	<.001
Lower extremities	0.79	0.72-0.86	<.001
Not specified	0.86	0.65-1.15	.316

Continued

Supplemental Table IV. Cont'd

Characteristic	Hazard ratio	95% CI	P value
Laterality			
Left	Reference		
Midline	1.21	1.12-1.31	<.001
Right	1.04	0.98-1.09	.19
Unknown	1.11	1-1.22	.048
Histologic type			
Superficial spreading	Reference		
Acral lentiginous	1.14	0.97-1.33	.109
Amelanotic	0.43	0.19-0.96	.039
Desmoplastic	0.71	0.63-0.8	<.001
Lentigo maligna	0.85	0.72-1	.048
Nodular	0.99	0.92-1.06	.716
Spindle	0.74	0.65-0.84	<.001
Other	1.1	0.87-1.4	.434
Unspecified	0.94	0.88-1	.068
Breslow depth			
1.01-2.00	Reference		
2.01-4	1.35	1.26-1.45	<.001
>4	2	1.85-2.15	<.001
Ulceration			
Not present	Reference		
Present	6.2	5.71-6.74	<.001
Unknown	1.2	1.14-1.26	<.001
Lymphovascular invasion			
Not present	Reference		
Present	1.73	1.46-2.05	<.001
Unknown	1.1	1.02-1.2	.02
Time to treatment			
1-29 d	Reference		
30-59 d	0.99	0.94-1.04	.771
60-89 d	0.96	0.88-1.04	.296
90-119 d	1.03	0.89-1.2	.647
≥120 d	1.06	0.89-1.26	.548

CI, Confidence interval.

Supplemental Table V. Multivariate analysis of melanoma by TNM stage III

Characteristic	Hazard ratio	95% CI	P value
Age at diagnosis			
<30	Reference		
30-39	1.32	1.12-1.56	.001
40-49	1.65	1.41-1.94	<.001
50-59	1.79	1.53-2.1	<.001
60-69	2.03	1.73-2.38	<.001
70-79	2.47	2.09-2.92	<.001
≥80	3.74	3.15-4.44	<.001
Sex			
Female	Reference		
Male	1.28	1.21-1.34	<.001
Charlson-Deyo comorbidity score			
0	Reference		
1	1.16	1.09-1.24	<.001
≥2	1.7	1.51-1.9	<.001
Insurance type/status			
	Reference		
Medicaid	1.32	1.09-1.6	.004
Medicare	1.09	0.92-1.28	.313
Not insured	1.13	0.94-1.37	.187
Other government	1.18	0.92-1.52	.2
Private insurance/managed care	0.86	0.73-1.01	.069
Facility type			
Academic/research program	Reference		
Community cancer program	1.08	0.98-1.18	.13
Comprehensive community cancer program	0.99	0.94-1.05	.781
Integrated network cancer program	1.02	0.92-1.13	.661
Facility location			
East north central	Reference		
East south central	1.16	1.04-1.28	.007
Middle Atlantic	0.96	0.89-1.05	.377
Mountain	0.96	0.86-1.08	.521
New England	0.91	0.81-1.02	.101
Pacific	0.97	0.88-1.06	.455
South Atlantic	1.01	0.93-1.08	.888
West north central	1.02	0.92-1.12	.732
West south central	1	0.9-1.12	.979
Primary site			
Head and neck	Reference		
Trunk	0.89	0.82-0.97	.007
Upper extremities	0.77	0.71-0.84	<.001
Lower extremities	0.79	0.72-0.86	<.001
Not specified	0.74	0.6-0.92	.006
Laterality			
Left	Reference		
Midline	1.12	1.02-1.22	.021
Right	0.99	0.94-1.04	.619
Unknown	1.04	0.95-1.15	.381

Continued

Supplemental Table V. Cont'd

Characteristic	Hazard ratio	95% CI	P value
Histologic type			
Superficial spreading	Reference		
Acral lentiginous	1.25	1.09-1.43	.001
Amelanotic	0.81	0.42-1.57	.534
Desmoplastic	0.65	0.51-0.83	.001
Lentigo maligna	0.92	0.74-1.16	.484
Nodular	1.05	0.98-1.13	.142
Spindle	0.85	0.69-1.04	.114
Other	0.98	0.77-1.24	.85
Unspecified	1.05	0.98-1.12	.152
Breslow depth			
<1 mm	Reference		
1.01-2.00 mm	0.82	0.76-0.89	<.001
2.01-4.00 mm	1.09	1.01-1.17	.024
>4 mm	1.62	1.51-1.73	<.001
Not specified	1.18	1.05-1.32	.005
Ulceration			
Not present	Reference		
Present	1.65	1.48-1.84	<.001
Unknown	1.51	1.44-1.59	<.001
Lymphovascular invasion			
Not present	Reference		
Present	1.57	1.4-1.76	<.001
Unknown	1.2	1.11-1.31	<.001
Time to treatment			
1-29 d	Reference		
30-59 d	1.03	0.98-1.09	.201
60-89 d	1.03	0.95-1.12	.436
90-119 d	0.97	0.85-1.12	.703
≥120 d	0.98	0.85-1.14	.836

CI, Confidence interval.